Best Peptides for Fat Loss Research: GLP-1 Agonists, GHRH Analogs, and Lipolytic Mechanisms

By Sam Smith

The fat loss peptide category spans roughly a 20-percentage-point range in clinical efficacy — from AOD-9604, which failed to achieve statistical significance in Phase 3 obesity trials, to retatrutide, which produced 24.2% average weight loss in Phase 2. That spread reflects genuinely different mechanisms operating at different points in energy metabolism, not just dose differences or formulation quality. Semaglutide and tirzepatide work centrally through appetite suppression and gastric emptying delay. Tesamorelin works peripherally through GH-mediated visceral fat lipolysis. AOD-9604 targets adipocyte lipase directly. MOTS-c operates through mitochondrial energy metabolism and AMPK activation. Each mechanism has a different clinical efficacy ceiling — and a different risk profile.

The GLP-1/GIP/glucagon agonist class has fundamentally changed the expectations benchmark for fat loss pharmacology. Before semaglutide's STEP trials published in 2021, a weight loss drug that achieved more than 5% body weight reduction in a meaningful proportion of patients was considered successful. STEP-1 reported 14.9% average weight loss at 68 weeks. Tirzepatide then pushed to 20.9% in SURMOUNT-1. Retatrutide appears to be pushing further still — and the trajectory of incretin pharmacology suggests we're not at the ceiling yet. For researchers studying fat loss peptides, that context is essential: comparisons against the pre-GLP-1 benchmark are no longer meaningful, and the relevant question is where on the efficacy spectrum a given compound sits relative to the current best-in-class.

This guide covers how each of the six major fat loss peptides works mechanistically, how they compare on efficacy, side effects, and selectivity for visceral versus subcutaneous fat, which mechanisms have the strongest human evidence versus primarily preclinical data, and what researchers should consider when selecting compounds for metabolic studies. Everything links to primary literature.

Can peptides help with fat loss?

Yes, with effect sizes ranging from modest (AOD-9604 at ~2-5 kg) to dramatic (retatrutide at 24.2 percent body weight). The GLP-1 class is the most clinically validated, with semaglutide and tirzepatide producing 10-20 percent average weight loss over 6-12 months in approved clinical use. The mechanism varies by compound; selecting the right peptide for the research or clinical question depends on whether the bottleneck is appetite, energy expenditure, visceral fat specifically, or general adipocyte biology.

GLP-1 receptor agonists: semaglutide and tirzepatide

The GLP-1 agonist class dominates the modern weight management landscape. Semaglutide (Wegovy/Ozempic) is the pure GLP-1 receptor agonist; tirzepatide (Zepbound/Mounjaro) is the dual GLP-1 + GIP agonist. Both produce appetite suppression that drives sustained negative energy balance. Published research shows that GLP-1 agonist treatment drives a 24% reduction in total energy intake across all ad libitum meals throughout the day in semaglutide-treated subjects. The hormone-mediated appetite signal is the central mechanism.

Average weight loss outcomes: semaglutide 2.4 mg over 68 weeks = 14.9 percent; tirzepatide 15 mg over 72 weeks = 20.9 percent. Both are once-weekly subcutaneous injection with stepwise dose escalation over 16-20 weeks. Both are approved by Health Canada and the FDA for chronic weight management.

Retatrutide: the triple agonist

Retatrutide is the next-generation incretin agonist still in Phase 3 trials. Published research shows that Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. The added glucagon receptor activation adds an energy-expenditure component that the dual agonist tirzepatide does not have, producing 24.2 percent average weight loss at the 12 mg dose over 48 weeks. Approval is expected 2027-2028 if Phase 3 data supports the Phase 2 efficacy signal.

Tesamorelin: visceral fat-specific lipolysis

Tesamorelin is a GHRH analogue with FDA approval for HIV-associated lipodystrophy. According to the PubMed-indexed Phase 3 trial paper, Tesamorelin reduces visceral fat by approximately 18% and improves body image distress over 26 weeks of daily injection. The visceral-fat selectivity is the mechanism distinguishing tesamorelin from the GLP-1 class: GH-mediated lipolysis preferentially mobilises visceral adipose tissue over subcutaneous fat because visceral adipocytes have higher GH receptor density. For research focused on belly fat specifically, tesamorelin is the most-validated tool.

AOD-9604: HGH fragment for direct lipolysis

AOD-9604 is a 16-amino-acid fragment of human growth hormone (residues 177-191) that isolates the lipolytic activity of HGH from its growth-promoting effects. Published research shows that the analogue of the hGH lipolytic domain may have the potential to be developed into a fat-specific intervention without the metabolic side effects of full HGH. Published data confirms that AOD9604 did not induce hyperglycaemia or reduce insulin secretion in subjects, distinguishing it from HGH which raises blood glucose.

Effect sizes are modest (2-5 kg over 12-24 weeks in Phase 2 trials), and the compound failed FDA approval for weight loss. It remains useful as a research tool for lipolysis biology research, particularly where GH-receptor activation would confound the analysis.

MOTS-c and metabolic biology

MOTS-c is a 16-amino-acid mitochondrial-derived peptide that activates AMPK and improves metabolic function in skeletal muscle and adipose tissue. Effects on body weight are documented in rodent models but human data is limited. The compound is included in fat-loss discussions because of its metabolic effects, but it is not in the same effect category as GLP-1 agonists. Researchers studying mitochondrial biology in fat metabolism contexts find MOTS-c useful; for primary fat-loss research, the GLP-1 class is more directly relevant.

What shreds belly fat the fastest?

“Belly fat” is a colloquial term that covers both subcutaneous abdominal fat (under the skin) and visceral fat (around organs). For visceral fat specifically, tesamorelin produces the most rapid and selective reduction (18 percent visceral fat reduction over 26 weeks). For total body weight including belly fat, retatrutide is the fastest at 24.2 percent over 48 weeks. For approved-medication access today, tirzepatide is the leading option. “Fastest” depends on whether we are measuring weeks to first effect (semaglutide and tirzepatide are similar; retatrutide is slightly faster) or absolute magnitude (retatrutide leads).

What peptide works like Ozempic?

Ozempic is semaglutide. The peptides that work through the same GLP-1 receptor mechanism include liraglutide (Saxenda), tirzepatide (Mounjaro/Zepbound, which adds GIP), retatrutide (which adds GIP and glucagon), and several earlier-stage GLP-1 agonists in development. Tirzepatide is the most-similar approved alternative with larger weight loss effects. For research, retatrutide is the cutting-edge alternative.

Side effects and safety

The GLP-1 class shares a common adverse event profile dominated by gastrointestinal symptoms:

• Nausea (most common, 30-50 percent at top doses)
• Vomiting (10-20 percent at top doses)
• Diarrhoea and constipation
• Injection-site reactions
• Modest heart rate increase
• Rare pancreatitis (precautionary class warning)
• Theoretical thyroid C-cell tumour signal in rodents (not confirmed in humans)

Tesamorelin’s adverse events are dominated by injection-site reactions, joint pain, and transient glucose elevation. AOD-9604 has minimal documented side effects. The mitochondrial-derived peptides (MOTS-c) have minimal documented effects in human use because exposure is limited.

Do you need a prescription for weight loss peptides?

In Canada and the United States, semaglutide and tirzepatide as finished pharmaceuticals (Ozempic, Wegovy, Mounjaro, Zepbound) require prescription. Tesamorelin (Egrifta) is prescription-only in the United States and not approved as a finished pharmaceutical in Canada. Research-grade material for all of these compounds is legal under research-use-only labelling without prescription, but is not the same product as the FDA/Health Canada-approved finished pharmaceuticals and should not be used as a self-administered weight-loss therapy.

How long does it take to see results?

Across the class: visible weight loss within 4-8 weeks of consistent dosing, substantial effects by 24-48 weeks, plateau around 60-72 weeks. The GLP-1 class produces 6-8 percent weight loss by 12 weeks at standard escalation; tesamorelin shows visible waist circumference change by 12 weeks; AOD-9604 produces visible body composition shift by 8-12 weeks though the magnitude is small. Maintenance of weight loss requires continued dosing; discontinuation typically allows weight to return toward baseline over 6-12 months.

Injectable vs oral peptides

Most of the leading fat-loss peptides require injection because peptide bioavailability is poor through the GI tract. Exceptions: oral semaglutide (Rybelsus) is FDA-approved, with lower bioavailability requiring a 7-mg or 14-mg daily dose vs the 2.4-mg weekly injection. AOD-9604 has some oral bioavailability. Most other peptides in this category (tesamorelin, retatrutide, MOTS-c) are injectable only.

Sourcing for research

Reproducible fat-loss research depends on the integrity of the input material:

• Batch-specific Certificate of Analysis from an independent third-party laboratory
• HPLC purity confirmation at 98 percent or above, with chromatogram trace
• Mass spectrometry verification of the expected molecular weight for each compound
• Endotoxin and sterility testing for in vivo or cell-culture work

Reviv Peptides supplies the canonical fat-loss research peptides with third-party COA and HPLC purity. View Semaglutide, Tirzepatide, Retatrutide, Tesamorelin, or AOD-9604.

Best peptides for fat loss questions

Can peptides help with fat loss?

Yes. Effect sizes range from modest (AOD-9604 at 2-5 kg) to dramatic (retatrutide at 24.2% body weight loss). The GLP-1 agonist class is the most clinically validated and produces 10-20% weight loss over 6-12 months in approved clinical use.

What are the best peptides for fat loss?

Semaglutide and tirzepatide (approved, large effects), retatrutide (experimental, largest effects), tesamorelin (visceral-fat specific, approved for HIV lipodystrophy), AOD-9604 (modest, research only). Selection depends on the target endpoint.

What peptides are similar to Ozempic for weight loss?

Ozempic is semaglutide. Similar mechanism peptides include liraglutide (Saxenda), tirzepatide (dual agonist with larger effects), and retatrutide (triple agonist still in trials).

Do peptides help reduce belly fat?

Yes. For visceral belly fat specifically, tesamorelin produces the most selective reduction (18% visceral fat over 26 weeks). For total body weight including abdominal fat, the GLP-1 class produces broader effects.

Are peptides safe for weight loss?

The approved GLP-1 agonists have well-characterised safety profiles dominated by GI side effects. Tesamorelin has favourable approved-product safety in HIV lipodystrophy. Research-use peptides have less comprehensive human safety data and should be used in research contexts only.

Key data point: The Phase 2 Retatrutide trial (Jastreboff et al., 2023, NEJM — PMID 37390186) documented mean body weight reduction of 24.2% at week 48 for the 12 mg dose — the largest weight loss recorded for any pharmacological intervention in a randomised controlled trial at that timepoint, establishing triple agonism as the most potent peptide-based fat loss mechanism in clinical research.

Summary

The best peptides for fat loss in current research and approved clinical use are the GLP-1 receptor agonists semaglutide and tirzepatide, the experimental triple agonist retatrutide, the GHRH analogue tesamorelin, the GH-fragment AOD-9604, and the mitochondrial-derived peptide MOTS-c. Effect sizes range from 2-5 kg (AOD-9604) to 24.2 percent body weight loss (retatrutide). Mechanism varies by compound: appetite suppression, energy expenditure, visceral lipolysis, direct adipocyte action, or mitochondrial metabolism. The right peptide depends on the specific research or clinical endpoint. Approved compounds (semaglutide, tirzepatide, tesamorelin) require prescription; research-grade material for all of these is legal in Canada and the United States under research-use-only labelling.

All products sold by Reviv Peptides are for research and educational purposes only and are not intended for human consumption.